Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay Bansal

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Nature Communications|April 3, 2026
Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signaturesNan Deng, Fahriye Duzagac, Ana M Bolivar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 28, 2013
Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasiaRajeswari Anaparthy, Srinivas Gaddam, Vijay Kanakadandi, et al.
Gastrointestinal Endoscopy|October 21, 2018
Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortiumMadhav Desai, David A Lieberman, Kevin F Kennedy, et al.
Journal of Clinical Gastroenterology|May 8, 2020
Low Risk of Progression of Barrett's Esophagus to Neoplasia in WomenJames E Allen, Madhav Desai, Carlijn A M Roumans, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 1, 2010
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinomaSachin Wani, Gary Falk, Matthew Hall, et al.
Endoscopy|April 25, 2015
Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort studyPreetika Sinh, Rajeswari Anaparthy, Patrick E Young, et al.
Gastroenterology|July 5, 2011
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagusSachin Wani, Gary W Falk, Jane Post, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal AdenocarcinomaNour Hamade, Sreekar Vennelaganti, Sravanthi Parasa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2023
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal AdenomaRobert E Schoen, Lisa A Boardman, Marcia Cruz-Correa, et al.
Frontiers in Immunology|June 4, 2026
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)Ajay Bansal, Elena M Stoffel, Ramona Lim, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Nature Communications|April 3, 2026
Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signaturesNan Deng, Fahriye Duzagac, Ana M Bolivar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 28, 2013
Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasiaRajeswari Anaparthy, Srinivas Gaddam, Vijay Kanakadandi, et al.
Gastrointestinal Endoscopy|October 21, 2018
Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortiumMadhav Desai, David A Lieberman, Kevin F Kennedy, et al.
Journal of Clinical Gastroenterology|May 8, 2020
Low Risk of Progression of Barrett's Esophagus to Neoplasia in WomenJames E Allen, Madhav Desai, Carlijn A M Roumans, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 1, 2010
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinomaSachin Wani, Gary Falk, Matthew Hall, et al.
Endoscopy|April 25, 2015
Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort studyPreetika Sinh, Rajeswari Anaparthy, Patrick E Young, et al.
Gastroenterology|July 5, 2011
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagusSachin Wani, Gary W Falk, Jane Post, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal AdenocarcinomaNour Hamade, Sreekar Vennelaganti, Sravanthi Parasa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2023
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal AdenomaRobert E Schoen, Lisa A Boardman, Marcia Cruz-Correa, et al.
Frontiers in Immunology|June 4, 2026
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)Ajay Bansal, Elena M Stoffel, Ramona Lim, et al.
Pageof 13